Cytogenix (fka CYGX)

[Paulness]

Don't let people convince you that todays PR is just old news, there is very good important new news mixed in like,

Dr. Cindee Ewell is a Ph.D. molecular biologist and an attorney who specializes in biotechnology patents. Dr. Ewell will work with our scientists and outside patent counsel to translate laboratory results into patent applications

The Company's research and development projects will result in clinically testable products. We have already discussed the anti-herpes and anti-microbial products above. We will complete our studies on our anti-inflammatory product

The plasmid DNA production will provide both a needed resource for our own clinical trials and a potential source of revenue. We are in preliminary discussions with three pharmaceutical companies about this technology. In this connection, we plan to undertake a major research program for DNA vaccines.

The combination of clinical tests and revenue from DNA production will strengthen the company and increase its value. The Company's strength and stability have attracted increasing interest by the financial community in providing support for the Company's continued growth

The breadth in our gene silencing technology platform continues to expand and we have developed several additional products against infectious diseases in pre-clinical development. These are under test now

2005 Will Be a Breakout Year